Comparative bioavailability study of Sildenafil 100 mg oral film vs. Viagra® 100 mg film-coated tablet administered to healthy men under fed conditions

IBSA Institut Biochimique (Switzerland)0 个研究点目标入组 35 人开始时间: 2023年1月10日最近更新: 2023年4月10日

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 35

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: Male

入选标准

•1. Informed consent: signed written informed consent before inclusion in the study
•2. Sex and Age: males, 18-55 years old inclusive
•3. Body Mass Index: 18.5-30 kg/m² inclusive
•4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
•5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study.

排除标准

•1. Electrocardiogram (12-lead ECG in supine position): clinically significant abnormalities; out of range intervals (PR <110 msec, PR >200 msec, QRS <60 msec, QRS >110 msec and QTc > 440 msec)
•2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study; presence or history (within 28 days) of any tongue piercings; presence of any partials, braces or dentures
•3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
•4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
•5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; history of vision or hearing problems related to drugs of the PDE5 inhibitor pharmacological class; history of priapism; anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease); history of ophthalmologic diseases like non-arteritic anterior ischemic optic neuropathy or retinitis pigmentosa
•6. Medications: medications, including over the counter (OTC) medications and herbal remedies for 2 weeks before the start of the study. Organic nitrates will not be allowed for 28 days before screening
•7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
•8. Blood donation: blood donations for 3 months before this study
•9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>2 drinks/day, defined according to the USDA Dietary Guidelines 2015-2020], caffeine (>5 cups coffee/tea/day) or tobacco abuse (?10 cigarettes/day)
•10. Drug test: positive result at the drug test at screening or day-1
•11. Alcohol test: positive alcohol breath test at day -1
•12. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians.

研究者

发起方

IBSA Institut Biochimique (Switzerland)

相似试验

已完成

1 期

Pharmacokinetics of a novel sildenafil orodispersible film administered by the supralingual and the sublingual route to healthy meUrological and Genital DiseasesErectile dysfunctionErectile Dysfunction

ISRCTN52182476IBSA Institut Biochimique (Switzerland)12

已完成

Unknown

Sildenafil bioequivalence

IRCT20130313012810N29Pharmachemei Pharmaceutical Co24

已完成

Unknown

Bioequivalence study of Sildenafil 100 mg tablet in 24 healthy male under fasting conditions

IRCT20180620040164N45Dorsa Pharmaceutical Co.24

已完成

1 期

Evaluation of Sildenafil in Treatment of Pediatrics Pulmonary Hypertensiopediatric pulmonary hypertension.Primary pulmonary hypertension

IRCT138805222342N1Mazandaran University of Medical Sciences30

已完成

4 期

Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet FormulationsHealthy Males

NCT00902512Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30